<DOC>
	<DOCNO>NCT00918476</DOCNO>
	<brief_summary>The purpose study estimate effect filibuvir pharmacokinetics ethinyloestradiol [ EE ] levonorgestrel [ LN ] , assess safety tolerability 600 mg BID filibuvir healthy woman investigate pharmacokinetics 600 mg BID filibuvir healthy woman .</brief_summary>
	<brief_title>Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives ( Levonorgestrel And Ethinyl Estradiol )</brief_title>
	<detailed_description>To investigate effect multiple oral dos filibuvir steady state pharmacokinetics oral contraceptive steroid healthy female subject .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy female subject age 18 45 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Subjects must combination ethinyl estradiol levonorgesterol oral contraceptive least one consecutive month prior Period 1 . Body Mass Index ( BMI ) approximately 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial . Willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Must willing practice alternative method contraception duration study addition oral contraceptive use . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any medical reason would contraindicate administration oral contraceptive ( per label ) . Including limited history unexplained vaginal bleeding , current breast cancer , active liver disease , uncontrolled hypertension , history diabetes vascular complication , history venous thrombosis , stroke , ischemic heart disease , history severe headache focal neurologic symptom . Female subject nonchildbearing potential meet follow criterion : Post menopausal , age 4555 amenorrheic &gt; 2 year meet criterion serum FSH level ( &gt; 30 IU/L ) , Females undergone hysterectomy , Females undergone tubal ligation , Females undergone bilateral oophorectomy . History discontinue use oral contraceptive medical reason . History febrile illness within 5 day prior first dose . Any condition possibly affect drug absorption ( eg , gastrectomy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>